```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:sssptau153cxa

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 25   CA/CAPLUS - Russian Agency for Patents and Trademarks
                   (ROSPATENT) added to list of core patent offices covered
 NEWS  4  FEB 28   PATDPAFULL - New display fields provide for legal status
                   data from INPADOC
 NEWS  5  FEB 28   BABS - Current-awareness alerts (SDIs) available
 NEWS  6  FEB 28   MEDLINE/LMEDLINE reloaded
 NEWS  7  MAR 02   GBFULL: New full-text patent database on STN
 NEWS  8  MAR 03   REGISTRY/ZREGISTRY - Sequence annotations enhanced
 NEWS  9  MAR 03   MEDLINE file segment of TOXCENTER reloaded
 NEWS  10 MAR 22   KOREAPAT now updated monthly; patent information enhanced
 NEWS  11 MAR 22   Original IDE display format returns to REGISTRY/ZREGISTRY
 NEWS  12 MAR 22   PATDPASPC - New patent database available
 NEWS  13 MAR 22   REGISTRY/ZREGISTRY enhanced with experimental property tags

 NEWS EXPRESS  JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:30:03 ON 01 APR 2005

=> file caplus uspatfull japio epfull medline biosis embase scisearch
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.84       0.84

FILE 'CAPLUS' ENTERED AT 14:32:21 ON 01 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 14:32:21 ON 01 APR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 14:32:21 ON 01 APR 2005
COPYRIGHT (C) 2005 Japanese Patent Office (JPO)- JAPIO

FILE 'EPFULL' ENTERED AT 14:32:21 ON 01 APR 2005
COPYRIGHT (C) 2005 European Patent Office / FIZ Karlsruhe

FILE 'MEDLINE' ENTERED AT 14:32:21 ON 01 APR 2005

FILE 'BIOSIS' ENTERED AT 14:32:21 ON 01 APR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 14:32:21 ON 01 APR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 14:32:21 ON 01 APR 2005
Copyright (c) 2005 The Thomson Corporation

=> s (autologous fibroblast#)
L1 820 (AUTOLOGOUS FIBROBLAST#)

=> s l1 and cultur?
L2 555 L1 AND CULTUR?

=> s l2 and (wound or fistula or ulcer or fistula) and heal?
L3 83 L2 AND (WOUND OR FISTULA OR ULCER OR FISTULA) AND HEAL?

=> s l3 and epithelial?
L4 46 L3 AND EPITHELIAL?

=> l4 and inject?
L4 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l4 and inject?
L5 30 L4 AND INJECT?

=> s l5 and ((non immunogen?) or nonimmunogen?)
L6 2 L5 AND ((NON IMMUNOGEN?) OR NONIMMUNOGEN?)

=> d l6 1-2 ibib abs

L6 ANSWER 1 OF 2 USPATFULL on STN
ACCESSION NUMBER: 2004:171982 USPATFULL
TITLE: Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
INVENTOR(S): DeAngelis, Paul L., Edmond, OK, UNITED STATES
Jing, Wei, Edmond, OK, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004132143	A1	20040708
APPLICATION INFO.:	US 2003-642248	A1	20030815 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-195908, filed on 15 Jul 2002, PENDING Continuation-in-part of Ser. No. US 1999-437277, filed on 10 Nov 1999, GRANTED, Pat. No. US 6444447 Continuation-in-part of Ser. No. US

1999-283402, filed on 1 Apr 1999, ABANDONED Continuation-in-part of Ser. No. US 2001-842484, filed on 25 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2002-142143, filed on 8 May 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404356P	20020816 (60)
	US 2003-479432P	20030618 (60)
	US 1998-107929P	19981111 (60)
	US 1998-80414P	19980402 (60)
	US 2000-199538P	20000425 (60)
	US 2001-289554P	20010508 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DUNLAP, CODDING & ROGERS P.C., PO BOX 16370, OKLAHOMA CITY, OK, 73113
NUMBER OF CLAIMS: 111
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 41 Drawing Page(s)
LINE COUNT: 8221
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methodology for polymer grafting by a polysaccharide synthase and, more particularly, polymer grafting using the hyaluronate or chondroitin or heparin/heparosan synthases from Pasteurella, in order to create a variety of glycosaminoglycan oligosaccharides having a natural or chimeric or hybrid sugar structure with a targeted size that are substantially monodisperse in size.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 2 USPATFULL on STN
ACCESSION NUMBER: 2004:24342 USPATFULL
TITLE: Bioadhesive directed somatic cell therapy
INVENTOR(S): Song, Sun Uk, Inchon, KOREA, REPUBLIC OF
Yi, Youngsuk, Gaithersburg, MD, UNITED STATES
Lee, Kwan Hee, Gaithersburg, MD, UNITED STATES
Noh, Moon Jong, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004018179	A1	20040129	
APPLICATION INFO.:	US 2003-382190	A1	20030305	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-369111P	20020329 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JHK Law, P.O. Box 1078, La Canada, CA, 91012-1078
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 1566
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention is related to a cell-mediated gene therapy treatment using a cell composition that includes bioadhesive material. The bioadhesive material allows targeted and localized delivery of therapeutic somatic cells to the site of interest.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> d his

     (FILE 'HOME' ENTERED AT 14:30:03 ON 01 APR 2005)

     FILE 'CAPLUS, USPATFULL, JAPIO, EPFULL, MEDLINE, BIOSIS, EMBASE,
     SCISEARCH' ENTERED AT 14:32:21 ON 01 APR 2005
L1          820 S (AUTOLOGOUS FIBROBLAST#)
L2          555 S L1 AND CULTUR?
L3           83 S L2 AND (WOUND OR FISTULA OR ULCER OR FISTULA) AND HEAL?
L4           46 S L3 AND EPITHELIAL?
L5           30 S L4 AND INJECT?
L6            2 S L5 AND ((NON IMMUNOGEN?) OR NONIMMUNOGEN?)

=> d l5 1-30 ibib abs

L5   ANSWER 1 OF 30  USPATFULL on STN
ACCESSION NUMBER:        2004:242059  USPATFULL
TITLE:                   Gene therapy using TGF-β
INVENTOR(S):             Noh, Moon Jong, Kyunggi-Do, KOREA, REPUBLIC OF
                         Kang, Kyoung Ae, Kyunggi-Do, KOREA, REPUBLIC OF
                         Lee, Kwan Hee, Seoul, KOREA, REPUBLIC OF
PATENT ASSIGNEE(S):      Tissuegene, Inc., Gaithersburg, MD, United States (U.S.
                         corporation)

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 6797703          B1   20040928
APPLICATION INFO.:       US 2000-702718           20001101  (9)
RELATED APPLN. INFO.:    Continuation-in-part of Ser. No. US 1999-345415, filed
                         on 30 Jun 1999, now patented, Pat. No. US 6315992
DOCUMENT TYPE:           Utility
FILE SEGMENT:            GRANTED
PRIMARY EXAMINER:        Wilson, Michael C.
LEGAL REPRESENTATIVE:    JHK Law, Kim, Joseph Hyosuk
NUMBER OF CLAIMS:        11
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT:              1094
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       The subject invention is related to a cell-mediated gene therapy
         treatment for orthopedic disease using a member belonging to the
         transforming growth factory-β (TGF-β) superfamily. TGF-β
         gene therapy as a new treatment method for degenerative arthritis is
         demonstrated. After transfection of TGF-β cDNA expression vectors
         into fibroblasts (NIH 3T3-TGF-β1), the cells were injected
         into rabbit achilles tendon and knee joints with artificially-made
         cartilage defects. Intratendinous injections were performed to
         determine the optimal concentration for in vivo expression. Partially
         defected cartilage model was made to simulate degenerative arthritis of
         the knee joint. The partial cartilage defect treated with the
         cell-mediated gene therapy procedure was covered by newly formed hyaline
         cartilage which indicates that the cells survived and stimulated matrix
         formation in this area. Completely denuded cartilage areas were covered
         by fibrous collagen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5   ANSWER 2 OF 30  USPATFULL on STN
ACCESSION NUMBER:        2004:171982  USPATFULL
TITLE:                   Targeted glycosaminoglycan polymers by polymer grafting
                         and methods of making and using same
INVENTOR(S):             DeAngelis, Paul L., Edmond, OK, UNITED STATES
                         Jing, Wei, Edmond, OK, UNITED STATES
```

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004132143	A1	20040708
APPLICATION INFO.:	US 2003-642248	A1	20030815 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-195908, filed on 15 Jul 2002, PENDING Continuation-in-part of Ser. No. US 1999-437277, filed on 10 Nov 1999, GRANTED, Pat. No. US 6444447 Continuation-in-part of Ser. No. US 1999-283402, filed on 1 Apr 1999, ABANDONED Continuation-in-part of Ser. No. US 2001-842484, filed on 25 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2002-142143, filed on 8 May 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404356P	20020816 (60)
	US 2003-479432P	20030618 (60)
	US 1998-107929P	19981111 (60)
	US 1998-80414P	19980402 (60)
	US 2000-199538P	20000425 (60)
	US 2001-289554P	20010508 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DUNLAP, CODDING & ROGERS P.C., PO BOX 16370, OKLAHOMA CITY, OK, 73113
NUMBER OF CLAIMS: 111
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 41 Drawing Page(s)
LINE COUNT: 8221
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methodology for polymer grafting by a polysaccharide synthase and, more particularly, polymer grafting using the hyaluronate or chondroitin or heparin/heparosan synthases from Pasteurella, in order to create a variety of glycosaminoglycan oligosaccharides having a natural or chimeric or hybrid sugar structure with a targeted size that are substantially monodisperse in size.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:113659 USPATFULL
TITLE: Delivery of therapeutic biologicals from implantable tissue matrices
INVENTOR(S): MacLaughlin, David T., Saugus, MA, UNITED STATES
Vacanti, Joseph P., Winchester, MA, UNITED STATES
Donahoe, Patricia K., Boston, MA, UNITED STATES
Masiakos, Peter T., Boston, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004086497	A1	20040506
APPLICATION INFO.:	US 2003-690077	A1	20031021 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-770339, filed on 26 Jan 2001, GRANTED, Pat. No. US 6692738

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-178842P	20000127 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FROMMER LAWRENCE & HAUG, 745 FIFTH AVENUE- 10TH FL., NEW YORK, NY, 10151

NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1458
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin.TM., interferons, andanti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells. Matrices can be formed of synthetic or natural materials, by chemical coupling at the time of implantation, using standard techniques for formation of fibrous matrices from polymeric fibers, and using micromachining or microfabrication techniques. These devices and strategies are used as delivery systems via standard or minimally invasive implantation techniques for any number of parenterally deliverable recombinant proteins, particularly those that are difficult to produce in large amounts and/or active forms using conventional methods of purification, for the treatment of a variety of conditions that produce abnormal growth, including treatment of malignant and benign neoplasias, vascular malformations (hemangiomas), inflammatory conditions, keloid formation, abdominal or plural adhesions, endometriosis, congenital or endocrine abnormalities, and other conditions that can produce abnormal growth such as infection. Efficacy of treatment with the therapeutic biologicals is detected by determining specific criteria, for example, cessation of cell proliferation, regression of abnormal tissue, or cell death, or expression of genes or proteins reflecting the above.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:57008 USPATFULL
TITLE: Delivery of bioactive compounds to an organism
INVENTOR(S): Vandenburgh, Herman H., Providence, RI, UNITED STATES
PATENT ASSIGNEE(S): Cell Based Delivery (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004043010	A1	20040304
APPLICATION INFO.:	US 2003-393143	A1	20030320 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-118950, filed on 17 Jul 1998, PENDING Continuation-in-part of Ser. No. US 1997-896152, filed on 17 Jul 1997, GRANTED, Pat. No. US 6503504 Continuation-in-part of Ser. No. US 1996-712111, filed on 13 Sep 1996, GRANTED, Pat. No. US 5869041 Continuation-in-part of Ser. No. US 1996-587376, filed on 12 Jan 1996, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1997-US303	19970110

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Page(s)
LINE COUNT: 3939
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed herein is a method of delivering a bioactive compound to an organism that involves growing individual cells in vitro under conditions that allow the formation of an organized tissue, at least a subset of the cells containing a foreign DNA sequence which mediates the production of the bioactive compound; and implanting the organized tissue into the organism, whereby the bioactive compound is produced and delivered to the organism. Also disclosed herein is an in vitro method for producing a tissue having in vivo-like gross and cellular morphology that involves providing precursor cells of the tissue; mixing the cells with a solution of extracellular matrix components to create a suspension; placing the suspension in a vessel having a three dimensional geometry approximating the in vivo gross and cellular morphology of the tissue and having attachment surfaces coupled thereto; allowing the suspension to coalesce; and **culturing** the cells under conditions in which the cells form an organized tissue connected to the attachment surfaces. Also disclosed herein is an apparatus for producing in vitro a tissue having in vivo-like gross and cellular morphology. This apparatus includes a vessel having a three dimensional geometry approximating the in vivo morphology of the tissue and tissue attachment surfaces coupled thereto.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:24342 USPATFULL
TITLE: Bioadhesive directed somatic cell therapy
INVENTOR(S): Song, Sun Uk, Inchon, KOREA, REPUBLIC OF
Yi, Youngsuk, Gaithersburg, MD, UNITED STATES
Lee, Kwan Hee, Gaithersburg, MD, UNITED STATES
Noh, Moon Jong, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004018179	A1	20040129	
APPLICATION INFO.:	US 2003-382190	A1	20030305	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-369111P	20020329	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JHK Law, P.O. Box 1078, La Canada, CA, 91012-1078
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 1566
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject invention is related to a cell-mediated gene therapy treatment using a cell composition that includes bioadhesive material. The bioadhesive material allows targeted and localized delivery of therapeutic somatic cells to the site of interest.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:7062 USPATFULL

TITLE: System and method for treating cardiac arrhythmias with fibroblast cells
INVENTOR(S): Lee, Randall J., Hillsborough, CA, UNITED STATES
Maciejewski, Mark J., Edina, MN, UNITED STATES
PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (U.S. corporation)
RHYTHM THERAPEUTICS CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005295	A1	20040108
APPLICATION INFO.:	US 2003-435714	A1	20030507 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-329295, filed on 23 Dec 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-379140P	20020508 (60)
	US 2002-426058P	20021113 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JOHN P. O'BANION, O'BANION & RITCHEY LLP, 400 CAPITOL MALL SUITE 1550, SACRAMENTO, CA, 95814
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 2294

AB A system delivers fibroblasts to a region of cardiac tissue at a location associated with a cardiac arrhythmia in a patient to form a conduction block in the region. A cardiac delivery system is coupled to a source the fibroblasts and delivers the fibroblasts to the location to form a conduction block. Substantial cardiac ablation is thus avoided. A contact member is shaped to correspond with a patterned region of tissue for delivering the fibroblasts along the pattern, such as linear, curvilinear, or circumferential patterns as required for treating particular arrhythmias. A pulmonary vein isolation assembly has an expandable or loop-shaped member cooperating with a needle array that delivers the fibroblast cells into a circumferential region of tissue engaged by the expandable member where a pulmonary vein extends from an atrium. Methods include providing the fibroblast cells as autologous cells in an **injectable** preparation.

L5 ANSWER 7 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:2717 USPATFULL
TITLE: System and method for forming a non-ablative cardiac conduction block
INVENTOR(S): Lee, Randall J., Hillsborough, CA, UNITED STATES
PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002740	A1	20040101
APPLICATION INFO.:	US 2003-434419	A1	20030507 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-329295, filed on 23 Dec 2002, PENDING Continuation-in-part of Ser. No. US 2003-349323, filed on 21 Jan 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-429914P	20021129 (60)
	US 2002-431287P	20021206 (60)

	US 2002-379140P	20020508 (60)
	US 2002-426058P	20021113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JOHN P. O'BANION, O'BANION & RITCHEY LLP, 400 CAPITOL MALL SUITE 1550, SACRAMENTO, CA, 95814	
NUMBER OF CLAIMS:	96	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Page(s)	
LINE COUNT:	2718	

AB A system forms a conduction block in a regions of cardiac tissue at a location associated with a cardiac arrhythmia by delivering a material that is non-ablative into the region. The material include living cells that do not form sufficient gap-junctions with cardiomyocytes to conduct, e.g. myoblasts, stem cells, or fibroblasts. The material may be a non-living agent, such as a polymer agent, e.g. fibrin glue agent or collagen agent. The material may be a combination of living and non-living material that enhances the cellular conduction block. A contact member delivers the material over a patterned region of tissue, such as arcuate, linear, or circumferential patterns. The contact member may include an expandable member or balloon. A guidewire may be used for delivery. Cells used may be autologous, prepared for **injection** with a kit. Conduction blocks are thus formed without substantially ablating cardiac tissue in the region.

L5 ANSWER 8 OF 30 USPATFULL on STN

ACCESSION NUMBER:	2003:276671 USPATFULL		
TITLE:	Methods of producing a library and methods of selecting polynucleotides of interest		
INVENTOR(S):	Zauderer, Maurice, Pittsford, NY, UNITED STATES Smith, Ernest S., Ontario, NY, UNITED STATES		
PATENT ASSIGNEE(S):	University of Rochester (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003194696	A1	20031016
APPLICATION INFO.:	US 2002-277161	A1	20021022 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-818991, filed on 28 Mar 2001, PENDING		
	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-192586P	20000328 (60)	
	US 2000-203343P	20000510 (60)	
	US 2001-263226P	20010123 (60)	
	US 2001-271426P	20010227 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	34 Drawing Page(s)		
LINE COUNT:	11239		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a high efficiency method of introducing DNA into linear DNA viruses such as poxvirus, a method of producing libraries in linear DNA viruses such as poxvirus, and methods of selecting or screening for polynucleotides of interest based on cell nonviability or other phenotypes of eukaryotic cells, especially mammalian cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2003:264795 USPATFULL
TITLE: Mixed-cell gene therapy
INVENTOR(S): Song, Sun Uk, Inchon, KOREA, REPUBLIC OF
Yi, Youngsuk, Gaithersburg, MD, UNITED STATES
Lee, Kwan Hee, Gaithersburg, MD, UNITED STATES
Noh, Moon Jong, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003185809	A1	20031002
APPLICATION INFO.:	US 2003-382137	A1	20030305 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-369162P	20020329 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JHK Law, P.O. Box 1078, La Canada, CA, 91012-1078
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 1306
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first population of mammalian cells transfected or transduced with a gene that is sought to be expressed, and a second population of mammalian cells that have not been transfected or transduced with the gene, wherein endogenously existing forms of the second population of mammalian cells are decreased at the target site, and wherein generation of the therapeutic protein by the first population of mammalian cells at the target site stimulates the second population cells to induce a therapeutic effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2003:176167 USPATFULL
TITLE: Non-viable keratinocyte cell composition or lysate for promoting **wound healing**
INVENTOR(S): Van Bossuyt, Hans, Relegem, BELGIUM
PATENT ASSIGNEE(S): N. V. Innogenetics S.A., BELGIUM (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6585969	B1	20030701
APPLICATION INFO.:	US 1999-243333		19990201 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-778031, filed on 2 Jan 1997, now patented, Pat. No. US 5866167 Division of Ser. No. US 1994-244177, filed on 22 Aug 1994, now patented, Pat. No. US 6126935		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1991-403137	19911120
	WO 1992-EP2657	19921119

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Naff, David M.
LEGAL REPRESENTATIVE: Merchant & Gould P.C.

NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1727
AB **Cultures** of keratinocyte cells are provided which are free from nonautologous fibroblasts and organ extracts, and which have a high speed of cell amplification for a minimum seeding density. The **cultures** can be cryopreserved in a buffered isotonic medium containing serum and a cryoprotectant. The **cultures** are produced by a process that does not involve the use of a feeder layer and organ extracts. A **culture** medium which can be used contains Medium 199, serum, epidermal growth factor, cholera toxin and/or hydrocortisone, and optionally insulin. A substance for **wound healing** and for cosmetic applications is derived from **cultured** human keratinocytes. A non-viable total keratinocyte lysate for use in promoting **wound healing** is produced by growing keratinocyte cells on a support, detaching the cells from the support, and lysing the detached cells to obtain the lysate which may be frozen and lyophilized. The cells may be grown without using a support to produce the lysate, or to produce a non-viable keratinocyte cell **culture** lyophilisate or spray dried non-viable keratinocyte cell composition for use in **healing** wounds.

L5 ANSWER 11 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2003:133458 USPATFULL
TITLE: Therapeutic cell preparation grafts and methods of use thereof
INVENTOR(S): Klein, Matthew B., Los Altos, CA, UNITED STATES
Cuono, Charles B., Chandler, AZ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003091543	A1	20030515	
APPLICATION INFO.:	US 2002-44004	A1	20020111	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-24057001	20011026

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ LEVIN COHN FERRIS GLOVSKY & POPEO, 666 THIRD AVENUE, NEW YORK, NY, 10017
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 1636
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A biological preparation including genetically modified cells together with biocompatible matrices and methods of use thereof are provided. The biological preparation is useful in treating a subject at risk for or suffering from a disease in a controllable dosage and time-dependent manner, and for in vitro and in vivo screening of candidate drug therapies

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2003:30210 USPATFULL
TITLE: Methods of producing a library and methods of selecting polynucleotides of interest
INVENTOR(S): Zauderer, Maurice, Pittsford, NY, UNITED STATES
Smith, Ernest S., Ontario, NY, UNITED STATES

PATENT ASSIGNEE(S): University of Rochester (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003022157	A1	20030130	
APPLICATION INFO.:	US 2001-818991	A1	20010328	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-192586P	20000328 (60)
	US 2000-203343P	20000510 (60)
	US 2001-263226P	20010123 (60)
	US 2001-271426P	20010227 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934
NUMBER OF CLAIMS: 137
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 31 Drawing Page(s)
LINE COUNT: 10535
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a high efficiency method of introducing DNA into linear DNA viruses such as poxvirus, a method of producing libraries in linear DNA viruses such as poxvirus, and methods of selecting polynucleotides of interest based on cell nonviability or other phenotypes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2003:4453 USPATFULL
TITLE: Method and apparatus for the photomodulation of living cells
INVENTOR(S): McDaniel, David H., Virginia Beach, VA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003004499	A1	20030102	
	US 6663659	B2	20031216	
APPLICATION INFO.:	US 2001-894899	A1	20010629	(9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-759094, filed on 12 Jan 2001, PENDING			

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-176175P	20000113 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Wayne C. Jaeschke, Jr., Morrison & Foerster LLP, Suite 5500, 2000 Pennsylvania Avenue, N.W., Washington, DC, 20006-1888
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Page(s)
LINE COUNT: 1819

AB The present invention relates to a system and method for the photomodulation of living tissue. When photomodulated, living tissue will exhibit bioactivation or bioinhibition according to the present invention and, when using the disclosed sources of narrowband multichromatic radiation can cause significant dermatologic advantages such as hair removal, hair growth stimulation, wrinkle reduction, acne reduction and scar removal, vitiligo, etc. The present invention has

application to non-dermatological medical treatments including tumor growth inhibition, cell regeneration, the stimulation of tissue in organs, etc.

L5 ANSWER 14 OF 30 USPATFULL on STN

ACCESSION NUMBER:	2002:303586 USPATFULL
TITLE:	Biological material for the repair of connective tissue defects comprising mesenchymal stem cells and hyaluronic acid derivative
INVENTOR(S):	Abatangelo, Giovanni, Via Pelosa 32, 35030 Saccolongo (Prov. of Padova), ITALY Callegaro, Lanfranco, Via Monte Grappa 6, 35016 Thiene (Prov. of Vicenza), ITALY Young, Randell G., 8418 West Grove Rd., Ellicott City, MD, United States 21043 Murphy, Josephine Mary, 2510 Pickwick Rd., Baltimore, MD, United States 21207 Fink, David Jordan, 303 Wendover Rd., Baltimore, MD, United States 21218 Bruder, Scott Philip, 3698 Ashley Way, Owings Mills, MD, United States 21117 Barry, Francis Peter, 2510 Pickwick Rd., Baltimore, MD, United States 21207 Kadiyala, Sudhakar, 1531 Lancaster St., Baltimore, MD, United States 21231 Caplan, Arnold I., 1300 Oakridge Dr., Cleveland Heights, OH, United States 44121 Moskowitz, Roland, 2846 Montgomery Rd., Shaker Heights, OH, United States 44122 Yoo, Jung U., 16301 Shaker Blvd., Shaker Heights, OH, United States 44122 Solchaga, Luis A., 2260 Barrington Rd., University Heights, OH, United States 44118

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6482231	B1	20021119
APPLICATION INFO.:	US 2000-602033		20000623 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-39200, filed on 13 Mar 1998, now abandoned Continuation-in-part of Ser. No. US 1998-41287, filed on 12 Mar 1998 Continuation-in-part of Ser. No. WO 1996-EP5093, filed on 19 Nov 1996		

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1995-PD225	19951120

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Isabella, David J.
LEGAL REPRESENTATIVE:	Hedman & Costigan, P.C.
NUMBER OF CLAIMS:	16
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	39 Drawing Figure(s); 34 Drawing Page(s)
LINE COUNT:	1013

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A biological material for the repair of connective tissue cells comprising:

a) a cell preparation enriched in mesenchymal stem cells,

b) three-dimensional extracellular matrix comprising a nyaluronic acid derivative.

The use of said biological material, optionally combined with therapeutically acceptable excipients and/or diluents and optionally in association with therapeutically effective ingredients in the repair of connective tissue cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 30 USPATFULL on STN

ACCESSION NUMBER:	2002:158078 USPATFULL
TITLE:	Artificial skin
INVENTOR(S):	van Blitterswijk, C. A., Hekendorp, NETHERLANDS van Dorp, Annette G. M., Alphen a/d Rijn, NETHERLANDS Ponec, M., Leiderdorp, NETHERLANDS Riesle, J. U., Amsterdam, NETHERLANDS
PATENT ASSIGNEE(S):	IsoTis N.V., Bilthoven, NETHERLANDS (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002082692	A1	20020627
APPLICATION INFO.:	US 2001-24360	A1	20011213 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-451520, filed on 30 Nov 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1998-204031	19981130
	EP 1998-204203	19981211

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	BANNER & WITCOFF, LTD., 28 STATE STREET, 28th FLOOR, BOSTON, MA, 02109
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1
LINE COUNT:	767

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to an artificial skin based on a copolymer of a polyalkylene glycol and an aromatic polyester, which skin has a thickness between 50 and 2000 μm, and which skin has an upper and a lower side, both having a macroporosity between 10% and 95%.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 30 USPATFULL on STN

ACCESSION NUMBER:	2002:101824 USPATFULL
TITLE:	Artificial skin
INVENTOR(S):	van Blitterswijk, C. A., Hekendorp, NETHERLANDS van Dorp, Annette G. M., Rijin, NETHERLANDS Ponec, M., Leiderdorp, NETHERLANDS Riesle, J. U., Amsterdam, NETHERLANDS
PATENT ASSIGNEE(S):	IsoTis N.V., Bilthoven, NETHERLANDS (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6383220	B1	20020507
APPLICATION INFO.:	US 1999-451520		19991130 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1998-204031	19981130
	EP 1998-204203	19981211

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: McDermott, Corrine
ASSISTANT EXAMINER: Barrett, Thomas
LEGAL REPRESENTATIVE: Banner & Witcoff, Ltd.
NUMBER OF CLAIMS: 72
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 898
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to an artificial skin based on a copolymer of a polyalkylene glycol and an aromatic polyester, which skin has a thickness between 50 and 2000 μm, and which skin has an upper and a lower side, both having a macroporosity between 10% and 95%.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 17 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2002:66628 USPATFULL
TITLE: DELIVERY OF BIOACTIVE COMPOUNDS TO AN ORGANISM
INVENTOR(S): VANDENBURGH, HERMAN H., PROVIDENCE, RI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002037279	A1	20020328
APPLICATION INFO.:	US 1998-118950	A1	19980717 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-896152, filed on 17 Jul 1997, PENDING Continuation-in-part of Ser. No. US 1996-712111, filed on 13 Sep 1996, GRANTED, Pat. No. US 5869041
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NIXON PEABODY LLP, ATTENTION: DAVID RESNICK, 101 FEDERAL STREET, BOSTON, MA, 02110
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Page(s)
LINE COUNT: 3958
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein is a method of delivering a bioactive compound to an organism that involves growing individual cells in vitro under conditions that allow the formation of an organized tissue, at least a subset of the cells containing a foreign DNA sequence which mediates the production of the bioactive compound; and implanting the organized tissue into the organism, whereby the bioactive compound is produced and delivered to the organism. Also disclosed herein is an in vitro method for producing a tissue having in vivo-like gross and cellular morphology that involves providing precursor cells of the tissue; mixing the cells with a solution of extracellular matrix components to create a suspension; placing the suspension in a vessel having a three dimensional geometry approximating the in vivo gross and cellular morphology of the tissue and having attachment surfaces coupled thereto; allowing the suspension to coalesce; and **culturing** the cells under conditions in which the cells form an organized tissue connected to the attachment surfaces. Also disclosed herein is an apparatus for producing in vitro a tissue having in vivo-like gross and cellular morphology. This apparatus includes a vessel having a three dimensional geometry approximating the in vivo morphology of the tissue and tissue attachment surfaces coupled thereto.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 18 OF 30 USPATFULL on STN

ACCESSION NUMBER: 2002:54341 USPATFULL
TITLE: Delivery of therapeutic biologicals from implantable tissue matrices
INVENTOR(S): MacLaughlin, David T., Saugus, MA, UNITED STATES
Vacanti, Joseph P., Winchester, MA, UNITED STATES
Donahoe, Patricia K., Boston, MA, UNITED STATES
Masiakos, Peter T., Boston, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002031500	A1	20020314	
	US 6692738	B2	20040217	
APPLICATION INFO.:	US 2001-770339	A1	20010126	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-178842P	20000127 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Patrea L. Pabst, Arnall Golden & Gregory, LLP, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA, 30309-3450
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin.TM., interferons, andanti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells. Matrices can be formed of synthetic or natural materials, by chemical coupling at the time of implantation, using standard techniques for formation of fibrous matrices from polymeric fibers, and using micromachining or microfabrication techniques. These devices and strategies are used as delivery systems via standard or minimally invasive implantation techniques for any number of parenterally deliverable recombinant proteins, particularly those that are difficult to produce in large amounts and/or active forms using conventional methods of purification, for the treatment of a variety of conditions that produce abnormal growth, including treatment of malignant and benign neoplasias, vascular malformations (hemangiomas), inflammatory conditions, keloid formation, abdominal or plural adhesions, endometriosis, congenital or endocrine abnormalities, and other conditions that can produce abnormal growth such as infection. Efficacy of treatment with the therapeutic biologicals is detected by determining specific criteria, for example, cessation of cell proliferation, regression of abnormal tissue, or cell death, or expression of genes or proteins reflecting the above.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 19 OF 30 USPATFULL on STN

ACCESSION NUMBER: 2001:223701 USPATFULL
TITLE: SKIN EQUIVALENT AND METHODS OF FORMING AND USING SAME
INVENTOR(S): HOEFFLER, WARREN, SAN CARLOS, CA, United States
NELSON, CHARLOTTE F., SUISUN, CA, United States
WANG, CHIAOYIN KATHY, PALO ALTO, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001048917	A1	20011206
APPLICATION INFO.:	US 1998-37191	A1	19980309 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FLEHR HOHBACH TEST, ALBRITTON & HERBERT LLP, SUITE 3400 FOUR EMBARCADERO CENTER, SAN FRANCISCO, CA, 94111
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1144
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for the formation of a mammalian skin equivalent are described herein. The method comprises mixing keratinocytes and fibroblasts. The mammalian skin equivalent is also described. The skin equivalent can be made to be normal, abnormal or aging.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 20 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2001:202190 USPATFULL
TITLE: Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-β-1
INVENTOR(S): Noh, Moon Jong, Kyunggi-Do, Korea, Republic of
Kang, Kyoung Ae, Kyunggi-Do, Korea, Republic of
Lee, Kwan Hee, Seoul, Korea, Republic of
PATENT ASSIGNEE(S): TissueGene Co., Gaithersburg, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6315992	B1	20011113
APPLICATION INFO.:	US 1999-345415		19990630 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Clark, Deborah J. R.
ASSISTANT EXAMINER: Wilson, Michael C.
LEGAL REPRESENTATIVE: Squire, Sanders & Dempsey LLP., Kim, Joseph Hyosuk
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 1136
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject invention is related to a cell-mediated gene therapy treatment for orthopedic disease using a member belonging to the transforming growth factor-β (TGF-β) superfamily. TGF-β gene therapy as a new treatment method for degenerative arthritis is demonstrated. After transfection of TGF-β cDNA expression vectors into fibroblasts (NIH 3T3-TGF-β1), the cells were **injected** into rabbit achilles tendon and knee joints with artificially-made cartilage defects. Intratendinous **injections** were performed to determine the optimal concentration for in vivo expression. Partially defected cartilage model was made to simulate degenerative arthritis of the knee joint. The partial cartilage defect treated with the cell-mediated gene therapy procedure was covered by newly formed hyaline cartilage which indicates that the cells survived and stimulated matrix

formation in this area. Completely denuded cartilage areas were covered by fibrous collagen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 21 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2000:131409 USPATFULL
TITLE: Pellets obtained from cell **cultures** of keratinocytes and their use in **wound healing**
INVENTOR(S): Van Bossuyt, Hans, Relegem, Belgium
PATENT ASSIGNEE(S): N.V. Innogenetics S.A., Belgium (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6126935		20001003	
	WO 9310217		19930527	
APPLICATION INFO.:	US 1994-244177		19940822	(8)
	WO 1992-EP2657		19921119	
			19940822	PCT 371 date
			19940822	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1997-91403137	19971120

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Marx, Irene
LEGAL REPRESENTATIVE: Merchant & Gould P.C.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1611
AB The present invention relates to a process for treating a skin surface **wound** of a human. The process includes topically applying a keratinocyte pellet fraction onto the **wound** to result in **wound** closure. The invention also relates to a pharmaceutical composition including a pharmaceutically acceptable vehicle and a keratinocyte pellet fraction. The keratinocyte pellet fraction can be produced in a sterile manner by growing a keratinocyte **culture**, lysing the keratinocytes, centrifugation, and recovering the keratinocyte pellet fraction.

L5 ANSWER 22 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2000:1537 USPATFULL
TITLE: Fibrillin 1 gene comprising duplication mutation and compositions and kits using the same
INVENTOR(S): Siracusa, Linda D., Cherry Hill, NJ, United States
Jimenez, Sergio A., Philadelphia, PA, United States
PATENT ASSIGNEE(S): Thomas Jefferson University, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6010694		20000104	
APPLICATION INFO.:	US 1996-687967		19960726	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-1561P	19950722 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted

PRIMARY EXAMINER: Stanton, Brian R.
ASSISTANT EXAMINER: Clark, Deborah J. R.
LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz Mackiewicz & Norris LLP
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1,4,7
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Human fibroblast cells that comprise a gene construct that comprises a duplication mutated fibrillin 1 gene operably linked to functional regulatory elements and compositions comprising such cells are disclosed. Methods of treating wounds and kits for practicing such methods are disclosed. Transgenic animals comprising a duplication mutated fibrillin 1 gene operably linked to a tissue specific and/or inducible promoter are disclosed. Methods of identifying individuals with a duplication mutated fibrillin 1 gene are disclosed. The methods comprises detecting a duplication of exons 17-40 of a fibrillin 1 gene or a gene product produced by expression of a duplication mutated fibrillin 1 gene. Methods of preventing expression of a duplication mutated fibrillin 1 gene are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 23 OF 30 USPATFULL on STN
ACCESSION NUMBER: 1999:15526 USPATFULL
TITLE: Non-viable total keratinocyte lysate for promoting **wound healing**
INVENTOR(S): Van Bossuyt, Hans, Relegem, Belgium
PATENT ASSIGNEE(S): N.V Innogentics S.A., Ghent, Belgium (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5866167		19990202
APPLICATION INFO.:	US 1997-778031		19970102 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-244177, filed on 22 Aug 1994

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1991-403137	19911120
	WO 1992-EP2657	19921119

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Naff, David M.
LEGAL REPRESENTATIVE: Merchant, Gould, Smith, Edell, Welter & Schmidt, P.A.
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1621

AB **Cultures** of keratinocyte cells are provided which are free from nonautologous fibroblasts and organ extracts, and which have a high speed of cell amplification for a minimum seeding density. Preferably, a **culture** contains no more than about 10% autologous non-keratinocyte cells such as star-shaped, non-keratinocyte cells and no more than about 1% **autologous fibroblasts**. The **cultures** can be cryopreserved in a buffered isotonic medium containing serum and a cryoprotectant. The **cultures** are produced by a process that does not involve the use of a feeder layer and organ extracts. A **culture** medium used contains Medium 199, serum, epidermal growth factor, cholera toxin and/or hydrocortisone, and optionally insulin. A substance for **wound healing** and for cosmetic applications is derived from **cultured** human

keratinocytes. Lyophilized keratinocyte cell **cultures** or an extract therefrom is used to provide a pharmaceutical composition. Confluent and cohesive keratinocyte sheets are prepared for use in **wound healing**. A non-viable total keratinocyte lysate for use in promoting **wound healing** is produced by growing keratinocyte cells on a support, detaching the cells from the support, and lysing the detached cells to obtain the lysate. The lysate may be frozen and lyophilized. The detached cells may be frozen to produce the lysate without lysis before freezing.

L5 ANSWER 24 OF 30 USPATFULL on STN

ACCESSION NUMBER:	1998:64722 USPATFULL
TITLE:	Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
INVENTOR(S):	Gage, Fred H., La Jolla, CA, United States Schinstine, Malcolm, San Diego, CA, United States Ray, Jasodhara, San Diego, CA, United States Friedmann, Theodore, La Jolla, CA, United States Kawaja, Michael D., Toronto, Canada Rosenberg, Michael B., San Diego, CA, United States Wolff, Jon A., Madison, WI, United States
PATENT ASSIGNEE(S):	The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5762926		19980609
APPLICATION INFO.:	US 1995-464397		19950605 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-209609, filed on 10 Mar 1994 which is a continuation of Ser. No. US 1991-792894, filed on 15 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1988-285196, filed on 15 Dec 1988, now patented, Pat. No. US 5082670		

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Chambers, Jasemine C.
ASSISTANT EXAMINER:	Hauda, Karen M.
LEGAL REPRESENTATIVE:	Merchant, Gould, Smith, Edell, Welter & Schmidt
NUMBER OF CLAIMS:	51
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	134 Drawing Figure(s); 70 Drawing Page(s)
LINE COUNT:	4865

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of genetically modifying donor cells by gene transfer for grafting into the central nervous system to treat defective, diseased or damaged cells are disclosed. The modified donor cells produce functional molecules that effect the recovery or improved function of cells in the CNS. Methods and vectors for carrying out gene transfer and grafting are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 25 OF 30 USPATFULL on STN

ACCESSION NUMBER:	97:63758 USPATFULL
TITLE:	Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
INVENTOR(S):	Gage, Fred H., La Jolla, CA, United States Friedmann, Theodore, La Jolla, CA, United States Rosenberg, Michael B., San Diego, CA, United States Wolff, Jon A., Madison, WI, United States

Schinstine, Malcolm, San Diego, CA, United States
Kawaja, Michael D., Toronto, Canada
Ray, Jasodhara, San Diego, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5650148		19970722
APPLICATION INFO.:	US 1994-209609		19940310 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-792894, filed on 15 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1988-285196, filed on 15 Dec 1988, now patented, Pat. No. US 5082670
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chambers, Jasemine C.
LEGAL REPRESENTATIVE: Merchant, Gould, Smith, Edell, Welter and Schmidt
NUMBER OF CLAIMS: 74
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 134 Drawing Figure(s); 70 Drawing Page(s)
LINE COUNT: 4924
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of genetically modifying donor cells by gene transfer for grafting into the central nervous system to treat defective, diseased or damaged cells are disclosed. The modified donor cells produce functional molecules that effect the recovery or improved function of cells in the CNS. Methods and vectors for carrying out gene transfer and grafting are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 26 OF 30 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 1999:81676 EPFULL
UPDATE DATE PUBLICAT.: 20050120
DATA UPDATE DATE: 20050119
DATA UPDATE WEEK: 200503
TITLE (ENGLISH): Artificial skin
TITLE (FRENCH): Peau artificielle
TITLE (GERMAN): Kunsthaut
INVENTOR(S): van Blitterswijk, Clemens Antoni, Hekendorpse Buurt 2, 3467 PD Hekendorp, NL; Ponec, Maria, Sternstraat 5, 2352 EH Leiderdorp, NL; van Dorp, Anette Geertruida Maria, Portugalstraat 22, 2408 CG Alphen a/d Rijn, NL; Riesle, Jens Uwe, Gerard Doustraat 192, 1073 XA Amsterdam, NL
PATENT APPLICANT(S): IsoTis N.V., Prof. Bronkhorstlaan 10, 3723 MB Bilthoven, NL
PATENT APPL. NUMBER: 3145730
AGENT: Prins, Adrianus Willem, Mr. Ir., et al, Vereenigde, Nieuwe Parklaan 97, 2587 BN Den Haag, NL
AGENT NUMBER: 20903
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
LANGUAGE OF PROCEDURE: English
LANGUAGE OF TITLE: German; English; French
DOCUMENT TYPE: Patent
PATENT INFO TYPE: EPB1 Granted patent
PATENT INFORMATION:

NUMBER	KIND	DATE
EP 1005873	B1	20030409

DESIGNATED STATES: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
APPLICATION INFO.: EP 1999-204039 A 19991130
PRIORITY INFO.: EP 1998-204031 A 19981130
EP 1998-204203 A 19981211
CITED PATENT LIT.: EP 243132 A
EP 357155 A
EP 416702 A
WO 9321858 A
US 3908201 A
US 5639654 A

L5 ANSWER 27 OF 30 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 1999:38490 EPFULL
DATA UPDATE DATE: 20011205
DATA UPDATE WEEK: 200149
TITLE (ENGLISH): Pellets derived from keratinocytes for use as **wound healing** substances
TITLE (FRENCH): Granules derives de keratinocytes utilisables commes agents pour le traitement de plaies
TITLE (GERMAN): Keratinozyt-abstammende Granulate zur Verwendung als wundheilendes Mittel
INVENTOR(S): VAN BOSSUYT, Hans, Onderrichtstraat 11, B-1731 Relegem, BE
PATENT APPLICANT(S): INNOGENETICS N.V., Industriepark Zwijnaarde 7, Box 4, 9052 Gent, BE
PATENT APPL. NUMBER: 713142
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
LANGUAGE OF PROCEDURE: English
LANGUAGE OF TITLE: German; English; French
DOCUMENT TYPE: Patent
PATENT INFO TYPE: EPA3 Separate publication of search report
PATENT INFORMATION:

NUMBER	KIND	DATE
EP 970701	A3	20011205

DESIGNATED STATES: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE
APPLICATION INFO.: EP 1999-114054 A 19921119
RELATED DOC. INFO.: EP 1992-923745 19930606
EP 615545 Parent Application
PRIORITY INFO.: EP 1991-403137 A 19911120

L5 ANSWER 28 OF 30 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 1997:57315 EPFULL
UPDATE DATE PUBLICAT.: 20050104
DATA UPDATE DATE: 20041222
DATA UPDATE WEEK: 200452
TITLE (ENGLISH): A VECTOR FOR POLYNUCLEOTIDE VACCINES
TITLE (FRENCH): VECTEUR DESTINE A DES VACCINS POLYNUCLEOTIDIQUES
TITLE (GERMAN): VEKTOR FUeR POLYNUKLEOTIDIMPFSTOFFE
INVENTOR(S): NELSON, Edward, L., 660 Buckhorn Road, Eldersburg, MD 21784, US; NELSON, Peter, J., Reutterstrasse 70, D-80689 Munich, DE
PATENT APPLICANT(S): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, (GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE; THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by;

HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF), The National Institute of Health, Office of Technology Transfer, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852, US

PATENT APPL. NUMBER: 304191
AGENT: Vossius, Volker, Dr., et al, Dr. Volker Vossius, Patentanwaltskanzlei - Rechtsanwaltskanzlei, Geibelstrasse 6, 81679 Muenchen, DE
AGENT NUMBER: 12524
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
LANGUAGE OF PROCEDURE: English
LANGUAGE OF TITLE: German; English; French
DOCUMENT TYPE: Patent
PATENT INFO TYPE: EPB1 Granted patent
PATENT INFORMATION:
PATENT INFORMATION:

NUMBER	KIND	DATE
NUMBER	KIND	DATE
EP 920522	B1	20031029
WO 9806863		19980219

DESIGNATED STATES: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

APPLICATION INFO.:	EP 1997-937243	A	19970814
	WO 1997-US14306	A	19970814
PRIORITY INFO.:	US 1996-23931P	P	19960814

CITED NON PATENT LIT.: COLOMA, M. JOSEFINA ET AL: "Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction" J. IMMUNOL. METHODS (1992), 152(1), 89-104 CODEN: JIMMBG;ISSN: 0022-1759, 1992, XP000289684;

PETER J. NELSON ET AL.: "Genomic organization and transcriptional regulation of the RANTES chemokine gene" JOURNAL OF IMMUNOLOGY, vol. 151, no. 5, 1 September 1993, BALTIMORE US, pages 2601-2612, - XP002047102 cited in the application

CITED PATENT LIT.:

WO 9201055	A
WO 9201307	A
WO 9507347	A
WO 9640987	A

L5 ANSWER 29 OF 30 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 1992:59902 EPFULL
DATA UPDATE DATE: 20000607
DATA UPDATE WEEK: 200023
TITLE (ENGLISH): THERAPY OF CENTRAL NERVOUS SYSTEM BY GENETICALLY MODIFIED CELLS
TITLE (FRENCH): THERAPIE DU SYSTEME NERVEUX CENTRAL A L'AIDE DE CELLULES MODIFIEES PAR GENIE GENETIQUE
TITLE (GERMAN): THERAPIE DES ZENTRALNERVENSYSTEMS MIT GENETISCH MODIFIZIERTEN ZELLEN
INVENTOR(S): GAGE, Fred, 8358 Caminito Helecho, La Jolla, CA 92037, US; FRIEDMANN, Theodore, 9470 La Jolla Shores Drive, La Jolla, CA 92037, US; ROSENBERG, Michael, B., 12688 Toreey Bluff Drive, No. 193, San Diego, CA 92130, US; WOLFF, Jon, A., 1122 University Bay Drive, Madison, WI 53705, US; SCHINSTINE, Malcolm, 12510 Caramel Creek Road Apt. 190, San Diego, CA 92130, US; KAWAJA, Michael, D., 1392 Brackenwood Crescent, Kingston Township, Ontario K7P 2W4, CA; RAY, Jasodhara, 4184

	Corte de la Siena, San Diego, CA 92130, US
PATENT APPLICANT(S):	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, (REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE; UNIVERSITY OF CALIFORNIA, THE REGENTS OF THE; CALIFORNIA, THE REGENTS OF THE UNIVERSITY OF), 300 Lakeside Drive, 22nd Floor, Oakland, California 94612-3550, US
PATENT APPL. NUMBER:	221072
AGENT:	VOSSIUS & PARTNER, Postfach 86 07 67, 81634 Muenchen, DE
AGENT NUMBER:	100311
LANGUAGE OF FILING:	English
LANGUAGE OF PUBL.:	English
LANGUAGE OF PROCEDURE:	English
LANGUAGE OF TITLE:	German; English; French
DOCUMENT TYPE:	Patent
PATENT INFO TYPE:	EPB1 Granted patent
PATENT INFORMATION:	
PATENT INFORMATION:	

NUMBER	KIND	DATE
NUMBER	KIND	DATE
EP 625195	B1	19990107
WO 9310234		19930527

DESIGNATED STATES:	AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE		
APPLICATION INFO.:	EP 1992-925278	A	19921113
	WO 1992-US9896	A	19921113
PRIORITY INFO.:	US 1991-792894	A	19911115

CITED NON PATENT LIT.: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 83, February 1986, WASHINGTON US pages 725 - 729 KHILLAN,J.S. ET AL. 'Developmental and tissue-specific expression directed by the alpha 2 type I collagen promoter in transgenic mice';
T. Palmer et al., Proc. Natl. Acad. Sci. USA, 88, pp 1330-1334, 1991

CITED PATENT LIT.:	EP 474979	A
	WO 8902468	A
	WO 9006757	A
	WO 9209688	A

L5 ANSWER 30 OF 30 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER:	1992:58924 EPFULL
DATA UPDATE DATE:	20010509
DATA UPDATE WEEK:	200119
TITLE (ENGLISH):	LYSATES DERIVED FROM KERATINOCYTES FOR USE AS **WOUND HEALING** SUBSTANCES
TITLE (FRENCH):	LYSATES DE KERATINOCYTES POUR UTILISATION COMME SUBSTANCES DE CICATRISATION
TITLE (GERMAN):	LYSATE VON KERATINOZYTEN ZUR VERWENDUNG ALS HEILMITTEL FUeR WUNDEN.
INVENTOR(S):	VAN BOSSUYT, Hans, Oudstrijdersstraat, 54 Bus 3, B-1785 Merchtem, BE
PATENT APPLICANT(S):	N.V. INNOGENETICS S.A., (INNOGENETICS S.A., N.V.), Industriepark Zwijnaarde 7, Box 4, 9052 Gent, BE
PATENT APPL. NUMBER:	713141
LANGUAGE OF FILING:	English
LANGUAGE OF PUBL.:	English
LANGUAGE OF PROCEDURE:	English
LANGUAGE OF TITLE:	German; English; French
DOCUMENT TYPE:	Patent
PATENT INFO TYPE:	EPB1 Granted patent
PATENT INFORMATION:	

PATENT INFORMATION:

	NUMBER	KIND	DATE
	NUMBER	KIND	DATE
	EP 615545	B1	20000517
	WO 9310217		19930527
DESIGNATED STATES:	AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE		
APPLICATION INFO.:	EP 1992-923745	A	19921119
	WO 1992-EP2657	A	19921119
RELATED DOC. INFO.:	EP 1999-114054		19990720
	EP 970701 Divisional Application		
PRIORITY INFO.:	EP 1991-403137	A	19911120

CITED NON PATENT LIT.:

IN VITRO vol. 16, no. 6, June 1980, US pages 516 - 525 D.M. PEEHL ET AL. 'Growth and differentiation of human keratinocytes without a feeder layer or conditioned medium';

DATABASE WPIL Week 8947, Derwent Publications Ltd., London, GB; AN 89-344184 (47) & JP,A,1 256 380 (TERUMO CORP) 12 October 1989;

JOURNAL OF CELL BIOLOGY vol. 79, no. 2, November 1978, US pages 356 - 370 C.L. MARCELO ET AL. 'Stratification, specialization, and proliferation of primary keratinocyte cultures' cited in the application;

MAYO CLINIC PROCEEDINGS vol. 61, no. 10, October 1986, ROCHESTER, MINNESOTA, US pages 771 - 777 M.R. PITTELKOW ET AL. 'New techniques for the in vitro culture of human skin keratinocytes and perspectives on their use for grafting of patients with extensive burns' cited in the application;

EMBASE, EXCERPTA MEDICA, AMSTERDAM, NL. ABSTRACT NO 81021358 D.M. PEEHL ET AL. 'Clonal growth of human keratinocytes with small amounts of dialyzed serum' & IN VITRO 1980, vol. 16, no. 6, pages 526 - 538;

Medline abstract of EP90203033;

Medline abstract of EP90308337;

Medline abstract of EP87110818;

Duinslaeger et al. (1996), Plast. Reconstr. Surg., 98, p.110-116;

Somers et al. (1996), Acta Otolaryngol, 116, p.589-593

CITED PATENT LIT.:

EP 296475	A
EP 364306	A
EP 403139	A
US 4254226	A
US 4443546	A
US 4673649	A